AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9923569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (50 mg)
Number of subjects: 53
Study 9923569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8067223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10
Study 8067223 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 10
Study 3057512 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 10
Study 3057512 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 10
Study 3057512 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg metamizole
Number of subjects: 10
Study 3057512 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg metamizole
Number of subjects: 10
Study 31216547 — intervention group
Group type: EXPERIMENTAL
Intervention: HULA (weighted hula-hooping for 6 weeks)
Number of subjects: 55
Study 31216547 — intervention group
Group type: COMPARATOR
Intervention: WALK (walking for 6 weeks)
Number of subjects: 55
Study 28072707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based strength training (physical exercise group)
Number of subjects: 66
Study 28072707 — intervention group
Group type: COMPARATOR
Intervention: Individual ergonomic training and education (reference group)
Number of subjects: 66
Study 25925999 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Tramadol (M + T)
Number of subjects: 87
Study 25925999 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Saline (M + S)
Number of subjects: 87
Study 25925999 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - no sedation
Number of subjects: 87
Study 22640573 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-focused virtual-reality games
Number of subjects: 36
Study 22640573 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic balance exercises
Number of subjects: 36
Study 21613037 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser at 1.5 W/100 Hz
Number of subjects: 50
Study 21613037 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser at 1.5 W/continuous wave (CW)
Number of subjects: 50
Study 21613037 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser at 3.0 W/100 Hz
Number of subjects: 50
Study 21613037 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser at 3.0 W/CW
Number of subjects: 50
Study 21613037 — intervention group
Group type: COMPARATOR
Intervention: No irradiation (Control)
Number of subjects: 50
Study 18760803 — intervention group
Group type: COMPARATOR
Intervention: NCPAP+6
Number of subjects: 15
Study 18760803 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC at 6 L/minute
Number of subjects: 15
Study 16946694 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 367
Study 16946694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 16946694 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg/day
Number of subjects: 367
Study 16946694 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 2 mg/day
Number of subjects: 367
Study 15770435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medication adherence
Number of subjects: 336
Study 15770435 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants, no formal educational qualifications, personal history of cardiovascular disease, lower total cholesterol level, greater difference between untreated cholesterol levels and current cholesterol levels
Number of subjects: 336
Study 15770435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower perceived risk of raised cholesterol, perceiving greater control over FH, perceiving genes and cholesterol to be important determinants of a heart attack
Number of subjects: 336
Study 15770435 — intervention group
Group type: EXPERIMENTAL
Intervention: Having personal history of cardiovascular disease, having no formal qualifications, perceiving genes to be important determinants of a heart attack
Number of subjects: 336
Study 15770435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention strategies aimed at helping patients to establish routines for medication taking
Number of subjects: 336
Study 11743151 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised structured feedback report concerning evaluations of care provided by their own patients.
Number of subjects: 3691
Study 9032500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin, 500 mg orally once daily for five consecutive days
Number of subjects: 20
Study 9032500 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base, 1000 mg orally four times daily for seven days
Number of subjects: 20
Study 8389738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (L) 10, 20, or 40 mg per day
Number of subjects: 91
Study 8389738 — intervention group
Group type: COMPARATOR
Intervention: Captopril (C) 25, 50, or 100 mg b.i.d.
Number of subjects: 91
Study 31809200 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency contraception (EC) awareness and knowledge assessment
Number of subjects: 0
Study 31809200 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude towards emergency contraception (EC)
Number of subjects: 0
Study 31327650 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min CWI at 8 °C (CWI-5)
Number of subjects: 10
Study 31327650 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-min CWI at 8 °C (CWI-2.5)
Number of subjects: 10
Study 31327650 — intervention group
Group type: COMPARATOR
Intervention: Passive rest
Number of subjects: 10
Study 28755622 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium-based treatment
Number of subjects: 482
Study 28755622 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine-based treatment
Number of subjects: 482
Study 28755622 — intervention group
Group type: COMPARATOR
Intervention: Randomized treatment (Lithium or Quetiapine)
Number of subjects: 482
Study 26381346 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based learning with voice-activated manikins
Number of subjects: 0
Study 26381346 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led basic life support
Number of subjects: 0
Study 23163412 — intervention group
Group type: EXPERIMENTAL
Intervention: Family obligation values
Number of subjects: 48
Study 21672502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 627
Study 18806703 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL[sharp]3 probiotic mixture
Number of subjects: 224
Study 18806703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 17409909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin (500 mg/m pemetrexed + 75 mg/m cisplatin)
Number of subjects: 187
Study 17409909 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed alone (500 mg/m)
Number of subjects: 187
Study 14657066 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 407
Study 11014759 — intervention group
Group type: EXPERIMENTAL
Intervention: False alarms present
Number of subjects: 69
Study 11014759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive support tool
Number of subjects: 69
Study 11014759 — intervention group
Group type: COMPARATOR
Intervention: Non-interactive support tool
Number of subjects: 69
Study 8784310 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth I procedure
Number of subjects: 62
Study 8784310 — intervention group
Group type: COMPARATOR
Intervention: Billroth II procedure
Number of subjects: 62
Study 1622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 355
Study 1622858 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery without neoadjuvant chemotherapy
Number of subjects: 355
Study 1622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Local resection
Number of subjects: 355
Study 1622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 355
Study 6147454 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist ranitidine (150 mg)
Number of subjects: 5
Study 6147454 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-receptor antagonist terfenadine (60 mg)
Number of subjects: 5
Study 31364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)
Number of subjects: 441
Study 31364286 — intervention group
Group type: COMPARATOR
Intervention: Sanger sequencing
Number of subjects: 441
Study 31364286 — intervention group
Group type: COMPARATOR
Intervention: Sanger sequencing followed by NGS
Number of subjects: 441
Study 31364286 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall detection rate
Number of subjects: 441
Study 30397706 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain
Number of subjects: 114
Study 30397706 — intervention group
Group type: EXPERIMENTAL
Intervention: i-Gel
Number of subjects: 114
Study 30397706 — intervention group
Group type: COMPARATOR
Intervention: ETT
Number of subjects: 114
Study 27085434 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased E/SRe ratio
Number of subjects: 121
Study 27085434 — intervention group
Group type: EXPERIMENTAL
Intervention: E/SRe
Number of subjects: 121
Study 27085434 — intervention group
Group type: COMPARATOR
Intervention: E/e' ratio
Number of subjects: 121
Study 25155138 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 303
Study 25155138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 303
Study 25155138 — intervention group
Group type: COMPARATOR
Intervention: No TXA
Number of subjects: 303
Study 22219414 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 50
Study 20432816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose isoflavone (16 mg)
Number of subjects: 12
Study 20432816 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose isoflavone (48 mg)
Number of subjects: 12
Study 20432816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20432816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 12
Study 17980248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (0.01 microg/kg/min with or without a 2-microg/kg bolus)
Number of subjects: 75
Study 17980248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water)
Number of subjects: 75
Study 17980248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 75
Study 17980248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 15063404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP), 750 microg, twice/day for 3 months
Number of subjects: 28
Study 15063404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15063404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 28
Study 12564092 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% trimecain infiltration into the thyroid capsule (n = 32)
Number of subjects: 64
Study 12564092 — intervention group
Group type: COMPARATOR
Intervention: Control group with saline infiltration into the thyroid capsule (n = 32)
Number of subjects: 64
Study 9839299 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MIU of IFN-beta-1a
Number of subjects: 49
Study 9839299 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MIU of IFN-beta-1a
Number of subjects: 49
Study 9839299 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta-1a (both doses)
Number of subjects: 49
Study 8206550 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 30
Study 8206550 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 30
Study 8206550 — intervention group
Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 30
Study 2674034 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/day)
Number of subjects: 10
Study 2674034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2674034 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 10
Study 5100372 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.5 mg oral administration in fasting state
Number of subjects: 21
Study 5100372 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.5 mg oral administration after food
Number of subjects: 21
Study 5100372 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin taken regularly in fasting state
Number of subjects: 21
Study 31773402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials evaluating interventions for osteoporosis
Number of subjects: 0
Study 31773402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0
Study 31773402 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to prevent fractures in osteoporosis
Number of subjects: 0
Study 29044408 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychological skill-building program (6-week duration)
Number of subjects: 42
Study 29044408 — intervention group
Group type: COMPARATOR
Intervention: Neutral control activities (6-week duration)
Number of subjects: 42
Study 26356395 — intervention group
Group type: COMPARATOR
Intervention: Phenazepam monotherapy
Number of subjects: 70
Study 26356395 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex treatment with selank and phenazepam
Number of subjects: 70
Study 23164702 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid fruit preload
Number of subjects: 34
Study 23164702 — intervention group
Group type: COMPARATOR
Intervention: Beverage fruit preload
Number of subjects: 34
Study 23164702 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid and beverage fruit and vegetable consumption for 8 weeks
Number of subjects: 34
Study 21103664 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion for one week
Number of subjects: 44
Study 19748294 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 47
Study 19748294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16750985 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bronchodilator response
Number of subjects: 1041
Study 16750985 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline log PC20
Number of subjects: 1041
Study 16750985 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FEV1
Number of subjects: 1041
Study 16750985 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 1041
Study 16750985 — intervention group
Group type: EXPERIMENTAL
Intervention: No controller medications
Number of subjects: 1041
Study 14571463 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n = 7)
Number of subjects: 14
Study 14571463 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 7)
Number of subjects: 14
Study 11081782 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 6614
Study 11081782 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 6614
Study 11081782 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive drugs (diuretics or beta-blockers)
Number of subjects: 6614
Study 8743589 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg caffeine
Number of subjects: 0
Study 8743589 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg caffeine
Number of subjects: 0
Study 8743589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8743589 — intervention group
Group type: EXPERIMENTAL
Intervention: Card version of the Stroop task
Number of subjects: 0
Study 8743589 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised version of the Stroop task
Number of subjects: 0
Study 1573097 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation imagery training (n = 39)
Number of subjects: 76
Study 1573097 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 37)
Number of subjects: 76
Study 2860336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg/puff, 3 times 2 puffs)
Number of subjects: 16
Study 2860336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg/puff, 3 times 3 puffs)
Number of subjects: 16
Study 2860336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg/puff, 3 times 4 puffs)
Number of subjects: 16
Study 2860336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times 4 puffs)
Number of subjects: 16
Study 30823944 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine citrate disodium
Number of subjects: 128
Study 30823944 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (Control)
Number of subjects: 128
Study 28295215 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical trainees
Number of subjects: 0
Study 28295215 — intervention group
Group type: COMPARATOR
Intervention: Experienced surgeons
Number of subjects: 0
Study 25852208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 922
Study 25852208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 922
Study 24375206 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI risperidone 12.5 to 50 mg per injection biweekly
Number of subjects: 0
Study 24375206 — intervention group
Group type: COMPARATOR
Intervention: Psychiatrist's choice of oral antipsychotics
Number of subjects: 0
Study 24375206 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI risperidone
Number of subjects: 0
Study 22025745 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone care intervention
Number of subjects: 819
Study 22025745 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 819
Study 19117039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of combined flutamide and goserelin before RT
Number of subjects: 378
Study 19117039 — intervention group
Group type: COMPARATOR
Intervention: 8 months of combined flutamide and goserelin before RT
Number of subjects: 378
Study 19117039 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative biopsies
Number of subjects: 378
Study 19117039 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate biopsies
Number of subjects: 378
Study 19117039 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive biopsies
Number of subjects: 378
Study 17143968 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD)
Number of subjects: 154
Study 17143968 — intervention group
Group type: COMPARATOR
Intervention: Conventional Syringe
Number of subjects: 154
Study 15189958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ppm O(3)
Number of subjects: 14
Study 15189958 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 14
Study 11375835 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 41
Study 11375835 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 41
Study 9660108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg/day
Number of subjects: 11
Study 7853126 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement plus collagen membrane
Number of subjects: 12
Study 7853126 — intervention group
Group type: COMPARATOR
Intervention: Flap debridement alone
Number of subjects: 12
Study 2551397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 2-deoxy-D-glucose (2DG) administration
Number of subjects: 0
Study 2551397 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrollable stress
Number of subjects: 0
Study 2551397 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parental loss
Number of subjects: 0
Study 1102149 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 16
Study 1102149 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 16
Study 31020621 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative film
Number of subjects: 300
Study 31020621 — intervention group
Group type: COMPARATOR
Intervention: Nonnarrative film
Number of subjects: 300
Study 31441419 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 34
Study 31441419 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral nutrition (DEN)
Number of subjects: 34
Study 31441419 — intervention group
Group type: EXPERIMENTAL
Intervention: EEN
Number of subjects: 34
Study 31441419 — intervention group
Group type: COMPARATOR
Intervention: DEN
Number of subjects: 34
Study 28731984 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (recently smoked cigarettes)
Number of subjects: 149
Study 28731984 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 149
Study 28731984 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 149
Study 25175554 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure massage three times a week for 30 minutes on the sanyinjiao (SP6), ciliao (BL32), and taichong (Liver 3) acupoints.
Number of subjects: 129
Study 25175554 — intervention group
Group type: COMPARATOR
Intervention: Manual of menstrual health education (Control group).
Number of subjects: 129
Study 25175554 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure intervention (Experimental group).
Number of subjects: 129
Study 23908318 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-FA
Number of subjects: 40
Study 23908318 — intervention group
Group type: COMPARATOR
Intervention: CWI
Number of subjects: 40
Study 23908318 — intervention group
Group type: COMPARATOR
Intervention: PL
Number of subjects: 40
Study 23908318 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-FA-CWI
Number of subjects: 40
Study 21741469 — intervention group
Group type: EXPERIMENTAL
Intervention: ArtTear
Number of subjects: 0
Study 21741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo A
Number of subjects: 0
Study 21741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo B
Number of subjects: 0
Study 21741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo C
Number of subjects: 0
Study 21741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo D
Number of subjects: 0
Study 21741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo E
Number of subjects: 0